检索结果-南通市图书馆

Functionalized liposomes for targeted breast cancer drug delivery

Bioactive Materials 2023年第6期24卷 401-437页

作者： Janske Nel Kamil Elkhoury Émilie Velot Arnaud Bianchi Samir Acherar Grégory Francius Ali Tamayol stéphanie grandemange Elmira Arab-Tehrany Universitéde Lorraine LIBioF-54000NancyFrance LAAS-CNRS F-31400ToulouseFrance Universitéde Lorraine CNRSIMoPAF-54000NancyFrance Universitéde Lorraine CNRSLCPMF-54000NancyFrance Universitéde Lorraine CNRSLCPMEF-54000NancyFrance Department of Biomedical Engineering University of Connecticut Health CenterFarmingtonCT06030USA Universitéde Lorraine CNRSCRANF-54000NancyFrance

Despite the exceptional progress in breast cancer pathogenesis,prognosis,diagnosis,and treatment strategies,it remains a prominent cause of female mortality ***,although chemotherapies are effective,they are associated with critical limitations,most notably their lack of specificity resulting in systemic toxicity and the eventual development of multi-drug resistance(MDR)cancer *** have proven to be an invaluable drug delivery system but of the multitudes of liposomal systems developed every year only a few have been approved for clinical use,none of which employ active *** this review,we summarize the most recent strategies in development for actively targeted liposomal drug delivery systems for surface,transmembrane and internal cell receptors,enzymes,direct cell targeting and dual-targeting of breast cancer and breast cancer-associated cells,e.g.,cancer stem cells,cells associated with the tumor microenvironment,etc.

关键词： Liposomes Breast cancer Anti-cancer agents Targeted drug delivery Surface functionalization Receptor-targeted drug delivery

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical Efficacy and Tolerability of Cimicoxib in Dogs with Osteoarthritis: A Multicentre Prospective study

引用

Open Journal of Veterinary Medicine 2014年第5期4卷 78-90页

作者： Joanna Murrell Erik grandemange Frederique Woehrle Julie Menard Kate White School of Veterinary Medicine and Science University of Nottingham Nottingham UK School of Veterinary Sciences University of Bristol Bristol UK Vetoquinol S.A. Centre de Recherche Lure France Vétoquinol S.A. Centre de Recherche Lure France Vétoquinol S.A. Paris France

Background: Cimicoxib is a coxib recently licensed in Europe for pain and inflammation associated with osteoarthritis (OA), and the management of perioperative pain due to orthopaedic or soft tissue surgery. Purpose: This prospective study was to complete the product information for the end users by providing additional scientific data obtained after a thirty-day treatment course of cimicoxib in dogs with OA, and to collect owners’ feedback. Data were collected from nine European countries with 492 client owned dogs recruited to the trial. Dogs were treated once daily with 2 mg/kg cimicoxib orally. Immediately before, at Day (D) 15 and D30 after the start of treatment veterinarians and owners scored body condition, appetite, locomotion, lameness, pain on palpation and manipulation of the joint and joint effusion (veterinarians) and dog demeanor and well being (owners). In a subset of dogs, serum urea (n = 191), creatinine (n = 184), Ast (n = 141) and ALT (n = 174) were measured at day (D) 0 and D30. statistical tests were carried out to detect significant changes in the clinical parameters with time. Results and Discussion: Veterinary and owner assessments were analysed from 236 and 215 dogs respectively. Improvements in locomotion, mobility, pain scores and dog demeanor and body condition were identified;outcome measures assessed by veterinarians continued to improve after 15 days of treatment up to the 30-day time point. At D30 a significantly higher number of dogs had an urea concentration superior to the upper limit of the reference range. However, there was no significant difference for creatinine, ALT and Ast. Conclusions: A 30-day treatment course with cimicoxib improved locomotion and decreased pain scores in dogs with OA, with minimal adverse effects. These data, support pre-clinical data in dogs receiving cimicoxib and are useful for veterinarians making decisions about which NSAID to administer to dogs that require pain management for OA.

关键词： Osteoarthritis Dogs NSAID Cimicoxib Pain Analgesia Owner Kidney Renal Mobility

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Field Comparison of the Impact of Different Treatment Durations in the Treatment of Acute Otitis Externa

引用

Open Journal of Veterinary Medicine 2013年第6期3卷 289-296页

作者： Erik grandemange Florence Pillet Olivier Roy Frédérique Woehrlé Vétoquinol Research Centre Lure Cedex France

Background: Acute otitis externa is a common multi-factorial disorder in the dog. Several topical preparations are available on the veterinary market, which are licensed for an either specified duration of treatment or for a discretionary period that is determined by the clinician. Objectives: To compare the efficacy of two topical products, both licensed for the treatment of otitis externa in the dog, but with different treatment durations. Animal Population: One hundred and sixty dogs were enrolled in this multicentre field study from which 157 dogs were analysed in the Per Protocol sample (73 Aurizon?treated animals and 84 Easotic?treated animals). Method: Dogs were randomly assigned to Aurizon?or Easotic?treatment groups. Aurizon?(Vétoquinol SA: marbofloxacin, clotrimazole, dexamethasone) was administered daily in the affected ear(s) for 7 or 14 days, and was compared with a daily administration of Easotic?(Virbac SAS: gentamicin, miconazole, hydrocortisone aceponate) for 5 days. General and localised clinical signs were scored on days 0 (D0), 3 (D3), 7 (D7), 14 (D14) and 21 (D21). Results: Clinical cure rates at the end of treatment were 56.3% and 48.8% (p=0.35) in the Aurizon?and Easotic?groups respectively and 81.2% versus 74.7% one week after completing the course of treatment (p = 0.34). Twenty-one days after initially presenting for the study, cure rates were 84.3% in the Aurizon?group and 73.8% in the Easotic?(p=0.12). A relationship between severity of clinical signs and treatment duration was observed. Conclusion and Clinical Significance: At the end of the trial period, cure rates showed a tendency to be higher in the Aurizon?treated animals. The flexible dosage and the veterinary monitoring permitted treatment duration to be adjusted based upon the severity of otitis externa thus increasing the likelihood of clinical cure.

关键词： Acute Otitis Externa Topical Ear Treatment Efficacy Field Clinical Trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

***公司发展的连轧管方法——NEUVAL

引用

钢管 1984年第Z1期 11-22页

作者： F. grandemange 汪汉明

近年来,连轧管方法得到了很大的改进。最重要的改进是在连轧管过程中使用限动芯棒,这种由法国Vallourec公司发展的新连轧管方法—NEUVAL已由圣索夫厂连轧管机组的生产实践说明了。

关键词：连轧管机芯棒荒管顶杆 NEUVAL Vallourec 芯棒轧制穿孔机轧辊公司发展

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：